Advanced Cancer, Breast Cancer, Colo-rectal Cancer, Endometrial Cancer, Lung Cancer, Lung Neoplasm, Neoplasm Malignant, Ovarian Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer
Conditions
Keywords
PVRIG, advanced cancer, checkpoint inhibitor, DNAM (DNAX Accessory molecule 1), PD-1 inhibitor, CD112, CD 112R, Poliovirus receptor-related immunoglobulin, PVRL2, Nivolumab, opdivo, TIGIT antibody, COM902
Brief summary
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Detailed description
This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with nivolumab in subjects with advanced solid tumors. Cohort expansion will be explored evaluating COM701 monotherapy and in combination with nivolumab in subjects with the following select tumor types (Non-Small cell lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and endometrial cancer. Other tumor types such as CRC-MSS, CRC-KRAS mutant will be enrolled based on emerging clinical activity data.
Interventions
DRUGCOM701
COM701 monotherapy.
DRUGCOM701 with Opdivo (Nivolumab).
COM701 in combination with Opdivo (Nivolumab).
Sponsors
Bristol-Myers Squibb
Compugen Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Subjects who received prior immune-stimulatory antitumor agents, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, OX-40, CD137, etc. are eligible. * Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all the available standard therapy or is not a candidate for the available standard therapy. Select Tumor Types (COM701 monotherapy cohort expansion; COM701 in combination with nivolumab): * Breast cancer (TNBC): Histologically confirmed incurable, advanced estrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) adenocarcinoma of the breast, as defined by the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines. Disease recurrence or progression during or after at least one systemic treatment that included an anthracycline and/or a taxane in the neoadjuvant, adjuvant, or metastatic setting. Subjects must have progressed after a poly ADP-ribose polymerase (PARP) inhibitor for patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutated metastatic breast cancer. P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort. * Endometrial cancer: Subjects with locally advanced or metastatic endometrial cancer, disease recurrence or progression during or after prior therapy that included platinum-based chemotherapy. P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort. * Ovarian cancer: Disease recurrence or progression during or after prior therapy that included: surgical resection, platinum agent, PARP inhibitor (for subjects with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer or as a maintenance therapy for subjects who have had complete or partial response to platinum-based therapy). P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort. * NSCLC: Documented stage IIIB or IV or recurrent NSCLC, Disease recurrence or progression during or after prior treatment that included: platinum agent, targeted therapy such as a TKI (if with biopsy-confirmed cytogenetic mutation eg EGFR, ROS, BRAF). COM701 monotherapy expansion cohort. * CRC (microsatellite stable, KRAS mutation) - P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort. * For Phase 1a monotherapy expansion and Phase 1b only: subject has at least one measurable lesion that could be followed during the study according to RECIST v1.1. Key
Exclusion criteria
* Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of COM701. * Symptomatic interstitial lung disease or inflammatory pneumonitis. * History of immune-related events that lead to immunotherapy treatment discontinuation. * Untreated or symptomatic central nervous system (CNS) metastases. * Impaired cardiac function or clinically significant cardiac disease, including any of the following: a) Unstable angina pectoris ≤ 6 months prior to first scheduled dose of COM701; b) Acute myocardial infarction ≤ 6 months prior to first scheduled dose of COM701.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs). | DLT evaluation window in the 1st cycle (21 or 28 days). | To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab. |
| Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab). | Approximately 2 year. | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of subjects with Anti-COM701 antibody. | Approximately 2 years. | Immunogenicity of COM701 monotherapy and in combination with nivolumab. |
| Overall Response Rate as per RECIST v1.1 | Approximately 2 years. | Preliminary antitumor activity of COM701 in combination with nivolumab. |
Countries
United States
Outcome results
None listed